pLOG

2026-01-08

Caizhao Strategy / Caiyao Biotech Successfully Renews SGS ISO 9001 Certification — Zero Nonconformities in Patient Support Program Quality Management

In the highly specialized and strictly regulated fields of pharmaceutical management and patient support services, a Quality Management System (QMS) is the cornerstone of service credibility and a tangible commitment to patient safety and privacy. The Caifeng Health Integrated Group (PatientsForce), with deep expertise in this domain, has once again successfully renewed its SGS ISO 9001 Quality Management System certification through its two core subsidiaries—Caizhao Strategy Consulting Co., Ltd. and Caiyao Biomedical Technology Co., Ltd. This achievement not only demonstrates the Group’s consistent commitment to quality excellence, but also lays a forward-looking foundation for digital advancement and sustainable development in 2026.

Eight Years of Unwavering Quality Commitment: QMS Safeguarding the Patient Journey

This ISO 9001 certification renewal continues a long-term commitment to quality that began with the Group’s initial certification in 2018. The scope of the certification covers both Caizhao Strategy and Caiyao Biomedical, demonstrating the Group’s success in embedding the same high-quality, high-standard management DNA across its service ecosystem. As the professional consulting arm of Caizhao Strategy and the core brand for intelligent healthcare under Caiyao Biomedical, PatientsForce delivers Patient Support Program (PSP) services with quality as its central mission.

For Patient Support Programs, a mature and robust QMS holds critical significance:

  • Enhanced Compliance and Transparency: Standardized, traceable, and measurable operational processes ensure that patient assistance and support services—such as PSP, PAP, drug safety, and disease management—are conducted at the highest regulatory and ethical standards, while also increasing service transparency.
  • Operational Stability and Sustainable Evolution: Since 2018, the continuous implementation of the PDCA (Plan–Do–Check–Act) cycle has enabled the Group to maintain operational stability in a rapidly changing biopharmaceutical environment, establishing itself as a trusted long-term Patient Solution Partner for international pharmaceutical companies and healthcare systems.
  • Foundation for ESG Governance: The Group regards ISO 9001 as a key cornerstone of corporate governance within its Environmental, Social, and Governance (ESG) framework, demonstrating its commitment to sustainable development.

 

Forward-Looking 2026 Strategy: Integrating AI Ethics and ESG into Risk Governance

Notably, in anticipation of the ISO 9001 revised standards set to be released in 2026, the company has demonstrated proactive readiness. As a key partner within the supply chain, the Group has already incorporated emerging risks into its governance framework, including:

  • AI Application Governance and Risk Assessment: Emphasizing data ethics, model reliability, and the protection of patient privacy.
  • Environmental and Climate Risk Assessment: Addressing ESG and sustainability trends by integrating environmental responsibility into service processes, with recognition including the EcoVadis medal and SBTi Net-Zero commitment.

Through the dedication of the company’s management team and Compliance Center, PatientsForce successfully passed the SGS ISO 9001 certification again in 2025. However, quality management certification is not an endpoint but a milestone in the ongoing, effective PDCA cycle. Looking ahead, the PatientsForce brand will continue to optimize every critical touchpoint in the patient journey—from pre-launch EAPs to post-launch PAPs and PSPs—transforming “compliance” into “demonstrable value” and co-creating a safer, smarter, and more sustainable service future for patients and healthcare systems.